Researchers identified CCT5 and ELF1 as significant biomarkers for determining treatment response and prognosis in locally advanced rectal cancer (LARC) patients undergoing neoadjuvant chemoradiotherapy (NCRT). Their study showed that high expression levels of these genes were associated with resistance to NCRT and poorer prognosis.
By analyzing gene expression and immune cell infiltration, the research developed a risk score model and nomograms, providing valuable tools for predicting patient outcomes and guiding personalized treatment.
Ref: Guan B, Xu M, Zheng R, Guan G, Xu B. Novel biomarkers to predict treatment response and prognosis in locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy. BMC Cancer. 2023;23(1). doi: https://doi.org/10.1186/s12885-023-11354-8